HIGH-DOSE IFN-ALPHA-2B VS CISPLATIN, VINBLASTINE, DTIC + IL-2 & IFN IN MELANOMA

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 [摘自ClinicalTrials.gov网站(编辑)] 干扰素α可能会干扰癌细胞的生长。化疗中使用的药物使用不同的方法来阻止肿瘤细胞分裂，从而停止生长或死亡。白介素2可以刺激人的白细胞杀死黑色素瘤细胞。目前尚不清楚单独服用干扰素1年以上是否比联合化疗和白介素2治疗3个月的黑色素瘤更有效。 这是一项随机的III期试验，目的是比较在接受或不接受顺铂、长春花碱、达卡巴津和白介素2的联合化疗的情况下，α干扰素在预防切除的高危黑色素瘤患者复发方面的有效性。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. [from ClinicalTrials.gov website (edited)] Interferon alfa may interfere with the growth of cancer cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Interleukin-2 may stimulate a person's white blood cells to kill melanoma cells. It is not yet known whether interferon alfa given alone over 1 year is more effective than interferon alfa given with combination chemotherapy and interleukin-2 for 3 months for melanoma. This is a randomized Phase III trial to compare the effectiveness of interferon alfa with or without combination chemotherapy consisting of cisplatin, vinblastine, and dacarbazine, plus interleukin-2, in preventing recurrences in patients with resected high-risk melanoma.